Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Imrnunoconjugate

Cancer Research

Volumn 51, Issue 10, 1991, Pages 2694-2698

  LeBerthon, Brian ^a   Khawli, Leslie A ^a   Alauddin, Mian ^a   Miller, Gordon K ^a   Charak, Bishan S ^a   Mazumder, Amitabha ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; IMMUNOTHERAPY; MOUSE; PRIORITY JOURNAL; TUMOR;

ANIMAL; ANTIBODIES, MONOCLONAL; BURKITT LYMPHOMA; CAPILLARY PERMEABILITY; CELL LINE; FEMALE; HUMAN; INTERLEUKIN-2; KINETICS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; REGIONAL BLOOD FLOW; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0025733498     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Epenetos, A. A., Snook, D., Durbin, H., Johnson, P. M., and Taylor-Papadimitriou, J. Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res., 46:3183-3191, 1986.
2. Jain, R. K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst., 81: 570-576, 1989.
3. Goldenberg, D. M. Targeting of cancer with radiolabeled antibodies. Arch. Pathol. Lab. Med., 112: 580-587, 1988.
4. Carrasquillo, J. A., Bunn, P. A., Keenan, A. M., Reynolds, J. C., Schroft, R. W., Foon, K. A., Ming-Hsu, S., Gazdar, A. F., Mulshine, J. L., Oldham, R. K., Perentesis, P., Horowitz, M., Eddy, J., James, P., and Larson, S. M. Radioimmunodetection of cutaneous T-cell lymphoma with 11'In-labeled T101 monoclonal antibody. N. Engl. J. Med., 315:673-680, 1986.
5. Dykes, P. W., Bradwell, A. R., Chapman, C. E., and Vaughan, A. T. M. Radioimmunotherapy of cancer: clinical studies and limiting factors. Cancer Treat. Rev., 14: 87-106, 1987.
6. Goodwin, D. A. Pharmacokinetics and antibodies. J. Nucl. Med., 28: 1358-1362, 1987.
7. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Lineham, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C. G., and White, D. E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or higher-dose interleukin-2 alone. N. Engl. J. Med., 316:889-897, 1987.
8. Rosenberg, S. A., Spiess, P., and Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (Washington DC), 233: 1318-1321,1986.
9. Sondel, P. M., Hank, J. A., Kohler, P. C., Sosman, J., Weil-Hillman, G., and Fisch, P. The cellular immunotherapy of cancer: current and potential uses of interleukin-2. Crit. Rev. Oncol. Hematol., 9: 125-147, 1989.
10. Smith, K. A. Interleukin-2: inception, impact, and implication. Science (Washington DC), 240: 1169-1176, 1988.
11. Ettinghausen, S. E., Puri, R. K., and Rosenberg, S. A. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated cells and recombinant interleukin-2 in mice. J. Natl. Cancer Inst., 80: 177-188, 1988.
12. Rosenstein, M., Ettinghausen, S. E., and Rosenberg, S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J. Natl. Cancer Inst., 137: 1735-1742, 1986.
13. Bucana, C. D., Trial, J., Papp, A. C., and Wu, K. K. Bovine aorta endothelial cell incubation with interleukin-2: morphological changes correlate with enhanced vascular permeability. Scanning Microsc., 2: 1559-1566, 1988.
14. Groenewegen, G., Buurman, W. A., and van der Linden, C. J. Lymphokines induce changes in morphology and enhance motility of endothelial cells. Clin. Immunol. Immunopathol., 36:378-385,1985.
15. Montesano, R., Orci, L., and Vassali, P. Human endothelial cell cultures: modulation by leukocyte interleukins. J. Cell. Physiol., 122:424-434, 1985.
16. Damle, N. K., and Doyle, L. V. IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. J. Immunol., 142: 2660-2669, 1989.
17. Epstein, A. L., Marder, R. J., Winter, J. N., Stathopoulos, E., Chen, F-M., Parker, J. W., and Taylor, C. R. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res., 47: 830-840, 1987.
18. Johnson, V. G., Scholm, J., Paterson, A., Bennett, J., Magnani, J. L., and Colcher, D. Analysis of human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res., 46: 850-857, 1986.
19. Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A. Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J. Exp. Med., 155: 1823-1841, 1982.
20. Mazumder, A., and Rosenberg, S. A. Successful immunotherapy of natural killer resistant established pulmonary melanoma metastasis by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J. Exp. Res., 159:495-507, 1984.
21. Epstein, A. L., Chen, F-M., and Taylor, C. R. A novel method for the detection of necrotic lesions in human cancers. Cancer Res., 48:5842-5848, 1988.
22. Sands, H., Shah, S. A., and Gallagher, B. M. Vascular volume and permeability of human and murine tumors grown in athymic mice. Cancer Lett., 27: 15-21, 1985.
23. Chen, F-M., Taylor, C. R., and Epstein, A. L. Tumor necrosis treatment of ME-180 human cervical carcinoma model with l3II-labeled TNT-1 monoclonal antibody. Cancer Res., 49:4578-4585, 1989.
24. DeNardo, S. J., DeNardo, G. L., O'Grady, L. F., Hu, E., Systma, V. M., Mills, S. L., Levy, N. B., Macey, D. J., Miller, C. H., and Epstein, A. L. Treatment of B-cell malignancies with 1-131 Lym-1 monoclonal antibodies. Int. J. Cancer, 5(Suppl.): 96-101, 1988.
25. DeNardo, G. L., DeNardo, S. J., O'Grady, L. F., Levy, N. B., Adams, G. P., and Mills, S. L. Fractionated radioimmunotherapy of B-cell malignancies with I31I-Lym-l. Cancer Res. (Suppl.) 50: 1014-1016, 1990.
26. Colcher, D., Hand, P. H., Nuti, M., and Scholm, J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc. Natl. Acad. Sci. USA, 78: 3199-3203, 1981.
27. Biddle, W. C., Pancook, J., Goldrosen, M., Han, T., and Foon, K. A., and Vaickus, L. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors. Cancer Res., 50: 2991-2996, 1990.
28. Gill, I., Agah, R., Hu, E., and Mazumder, A. Synergistic antitumor effects of interleukin 2 and the monoclonal antibody Lym-1 against human Burkitt's lymphoma cells in vitro and in vivo. Cancer Res., 49: 5377-5379, 1989.
29. Schultz, K. R., Klarnet, J. P., Peace, D. J., Cheever, M. A., Badger, C. C., Bernstein, I. D., and Greenberg, P. D. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells. Cancer Res., 50: 5421-5425, 1990.